In a Phase 3 trial reported earlier this year, an experimental Regeneron Pharmaceuticals therapy dosed just four times a year produced rapid and sustained disease control in generalized myasthenia gravis, a chronic autoimmune disorder that weakens the muscles. On June 22, Regeneron said regulators on both sides of the Atlantic had accepted the drug for review.
Regeneron sits in the portfolios of numerous institutional investors, including hedge funds such as Armistice Capital, which reported a position in its most recent 13F filing.
Treating Generalized Myasthenia Gravis
Generalized myasthenia gravis is a chronic autoimmune condition in which antibodies disrupt communication between nerves and muscles, causing weakness that can affect the eyes, limbs, and, in severe cases, the muscles used to breathe. Most patients carry antibodies against the acetylcholine receptor, and the immune attack is driven in part by the complement system.
Cemdisiran, the therapy under review, is an investigational small interfering RNA treatment. It works by suppressing the liver’s production of complement component C5, a protein in that cascade, which sets it apart from the C5 antibodies already on the market that bind the protein directly.
Regeneron holds worldwide rights to the molecule through a longstanding collaboration with Alnylam Pharmaceuticals, a pioneer of RNA-interference drugs.
The regulatory submissions rest on the Phase 3 NIMBLE trial, a randomized, double-blind, placebo-controlled study of 284 patients. It tested cemdisiran given subcutaneously every 12 weeks, both on its own and in combination with pozelimab, a C5 antibody, against placebo. The trial met its primary and key secondary endpoints at week 24, and full results were published in The Lancet and presented at the American Academy of Neurology annual meeting in April 2026. The every-12-weeks schedule is central to the drug’s positioning: many existing gMG therapies require far more frequent dosing.
In announcing the topline results in April, Regeneron described the effect as rapid, deep, and sustained disease control. For a condition managed over decades, a therapy that holds symptoms in check with an injection once a quarter would ease a treatment burden that, with some existing options, means infusions or injections every few weeks. That practical difference, as much as the efficacy data, is what the company is betting will matter to neurologists and patients weighing their choices.
Two Review Gates
On June 22, Regeneron said the FDA and the European Medicines Agency had accepted its applications for cemdisiran in adults with generalized myasthenia gravis who are anti-AChR antibody-positive.
The FDA granted Priority Review, with a target action date in November 2026, after the company used a priority review voucher. A European Commission decision is anticipated in the second half of 2027, and a filing in Japan is planned for early 2027. The reviews will run on separate clocks.
A Crowded Field
The field is already crowded. Complement inhibitors such as eculizumab, ravulizumab, and zilucoplan compete with FcRn-targeted drugs including efgartigimod and rozanolixizumab. Regeneron’s pitch centers on convenience. But if approved, cemdisiran would be the only subcutaneous option given four times a year, and potentially the first siRNA therapy in the disease.
The gMG program is one of several late-stage efforts at the company. In a separate decision, the FDA in November 2025 approved EYLEA HD, Regeneron’s high-dose eye medicine, for macular edema following retinal vein occlusion, with dosing intervals of up to eight weeks. That approval extended the reach of the company’s retina franchise, which along with the immunology drug Dupixent, marketed with Sanofi, generates the bulk of its revenue. Cemdisiran is an effort to add a new therapeutic area to that base rather than a replacement for it.
Regeneron’s shareholder base is dominated by large asset managers. Vanguard, BlackRock, State Street, and Dodge & Cox rank among the major holders, with hedge funds including Armistice Capital also reporting positions in the fund’s institutional portfolio.
For investors tracking the name, the November action date on cemdisiran is the next concrete milestone, set against a competitive market where dosing frequency and route of administration increasingly shape uptake.
